Search
Search Results
-
The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy
BackgroundMolecular imaging is pivotal in staging and response assessment of children with neuroblastoma (NB). [ 123 I]-metaiodobenzylguanidine (mIBG)...
-
Optimal Protocol and Clinical Usefulness of 123I-MIBG Cardiac Scintigraphy for Differentiation of Parkinson’s Disease and Dementia with Lewy Body from Non-Parkinson’s Diseases
Purpose123 I-metaiodobenzylguanidine (MIBG) cardiac scintigraphy was a useful imaging modality for the diagnosis of Parkinson’s disease, but its...
-
Absolute quantitation of sympathetic nerve activity using [123I] metaiodobenzylguanidine SPECT-CT in neurology
Background and purposeThe ability of [ 123 I]metaiodobenzylguanidine (MIBG) sympathetic nerve imaging with three-dimensional (3D) quantitation to...
-
Reduced 123I-MIBG uptake in the parotid and submandibular glands in patients with Parkinson’s disease identified using a quantitative semi-automatic method
ObjectivesTo analyze 123 I-metaiodobenzylguanidine (MIBG) uptake in the parotid and submandibular glands in patients with Parkinson’s disease (PD) in...
-
Comparison of the detecting capability between 123I-mIBG and post-therapeutic 131I-mIBG scintigraphy for curie scoring in patients with neuroblastoma after chemotherapy
ObjectiveTo evaluate the detecting capability between planar imaging (PI) and PI combined with single-photon emission computed tomography/computed...
-
Sympathetic 123I-metaiodobenzylguanidine index for Lewy body disease: probability-based diagnosis and identifying patients exempt from late imaging
ObjectiveWe aimed to establish a practical diagnostic index for Lewy body diseases (LBD), such as Parkinson’s disease and dementia, with Lewy bodies...
-
Predicting event-free survival after induction of remission in high-risk pediatric neuroblastoma: combining 123I-MIBG SPECT-CT radiomics and clinical factors
BackgroundAccurately quantifying event-free survival after induction of remission in high-risk neuroblastoma can lead to better subsequent treatment...
-
Safety and efficacy of multiple-dose versus single-dose MIBG therapy in patients with refractory pheochromocytoma and paraganglioma: a single-center retrospective analysis
ObjectiveTo investigate the incidence of adverse events (AEs) following single and multiple administrations of I-131 metaiodobenzylguanidine (MIBG)...
-
A Pictorial Review of I-123 MIBG Imaging of Neuroblastoma Utilizing a State-of-the-Art CZT SPECT/CT System
The field of nuclear medicine is entering a new era of gamma-camera technology. Solid-state SPECT/CT systems will gradually replace the...
-
Thyroid function after diagnostic 123I-metaiodobenzylguanidine in children with neuroblastic tumors
BackgroundMetaiodobenzylguanidine (MIBG) labeled with radioisotopes can be used for diagnostics 123 I − ) and treatment ( 131 I − ) in patients with...
-
123I metaiodobenzylguanidine (MIBG) uptake predicts early relapse of neuroblastoma using semi-quantitative SPECT/CT analysis
Objective123 I metaiodobenzylguanidine (MIBG) scintigraphy is a useful tool for the diagnosis of neuroblastoma (NB). MIBG uptake is correlated with...
-
Usefulness of semi-quantitative analysis in 123I metaiodobenzylguanidine SPECT/CT for the differentiation of pheochromocytoma and cortical adenoma
Objective123 I metaiodobenzylguanidine (MIBG) scintigraphy is a useful tool for the diagnosis of pheochromocytomas (PHEOs), but some PHEOs are...
-
Does the Incremental Value of 123I-Metaiodobenzylguanidine SPECT/CT over Planar Imaging Justify the Increase in Radiation Exposure?
PurposePlanar scintigraphy with 123 I-radiolabeled metaiodobenzylguanidine ( 123 I-mIBG) is an important imaging modality to evaluate neuroblastoma. In...
-
Machine learning-based prediction of conversion coefficients for I-123 metaiodobenzylguanidine heart-to-mediastinum ratio
PurposeWe developed a method of standardizing the heart-to-mediastinal ratio in 123 I-labeled meta -iodobenzylguanidine (MIBG) images using a...
-
Prognostic value of [18F]FDG-PET prior to [131I]MIBG treatment for pheochromocytoma and paraganglioma (PPGL)
ObjectivePheochromocytomas and paragangliomas (PPGLs) are rare tumors arising from the neural crest cells that form the sympathetic and...
-
Application of 123I-MIBG myocardial maximum standardized uptake value to characterize cardiac function in patients with pheochromocytoma: comparison with echocardiography
PurposeThis study examined the usefulness of the maximum standardized uptake value (SUVmax) of myocardial [ 123 I]-metaiodobenzylguanidine ([ 123 I]-MIBG...
-
Quality and utility of [123I]I-metaiodobenzylguanidine cardiac SPECT imaging in nondiabetic postinfarction heart failure patients qualified for implantable cardioverter defibrillator
ObjectiveImpaired cardiac adrenergic activity has been demonstrated in heart failure (HF) and in diabetes mellitus (DM). [ 123 I]I-metaiodobenzylguanid...
-
Cardiac 123I-mIBG scintigraphy for prediction of catheter ablation outcome in patients with atrial fibrillation
BackgroundPrevious studies show inconsistent results on the role of innervation imaging (with 123 I-mIBG) in predicting late atrial fibrillation (AF)...
-
Convolutional neural network-based automatic heart segmentation and quantitation in 123I-metaiodobenzylguanidine SPECT imaging
BackgroundSince three-dimensional segmentation of cardiac region in 123 I-metaiodobenzylguanidine (MIBG) study has not been established, this study...
-
Prognostic factors for refractory pheochromocytoma and paraganglioma after 131I-metaiodobenzylguanidine therapy
ObjectiveGiven the rarity of refractory pheochromocytoma and paraganglioma (PPGL), outcomes and prognostic factors after 131 I-metaiodobenzylguanidine...
